Will CRISPR gene therapy ever recover?

Given how badly the CRISPR-based companies are suffering (lack of funding, high risk, costly R&D, manufacturing, regulation, patient hesitancy, etc) and all their lay-offs, do you think the field will ever recover? Even when the investors put their risk-taking hat on, will they ever reconsider putting their money into genome editing?